SEATTLE, June 01, 2021, (MEDGADGET) — Overview:
Chordoma is a rare cancer that affects the spine or the area between the base of the skull and the tailbone. Chordoma is a form of sarcoma, which are cancerous tumours of the bones and soft tissues. The most common sacral and cervical spine tumours are Chordomas.
Chordoma tumours effect on the spine, brain, and nerves, causing tingling, numbness, fatigue, loss of bladder or bowel control, sexual dysfunction, vision problems, endocrine problems, and swallowing problems.
Chordomas are handled differently depending on their size, position, and appearance. Chordomomas can recur or spread in other parts of the body even after surgical treatment. Chordomas usually affect the bones, lungs, liver, and lymph nodes. Surgery, radiation therapy, targeted therapy, and advanced chemotherapies are among the treatment choices. Targeted therapy, in which medications are used to directly target cancerous cells, is the most effective procedure.
For More Information, Request Sample Copy Of Business Report: https://www.coherentmarketinsights.com/insight/request-pdf/3979
Drivers:
Rise in drug approvals from regulatory authorities for chordoma treatment is expected to fuel the growth of chordoma disease therapeutics market. For instance, The United States Food and Drug Administration (FDA) granted orphan drug status to Bavarian Nordic A/BN-Brachyury, S’s a novel cancer vaccine indicated for the treatment of chordoma, in May 2018.
Key players focusing on adoption of strategies such as collaborations and agreements to strengthen their position in the market are expected to drive the growth of the chordoma disease therapeutic market. For instance, Biothera Pharmaceuticals signed a licencing agreement with Cipla Limited in January 2019 for BAT1706, a possible bevacizumab biosimilar. Cipla Limited secured the rights to distribute and sell the biosimilar in emerging markets as part of this deal.
Covid-19 Impact:
Chemotherapy and other cancer therapies may weaken cancer patients’ immune systems, raising their risk of infection. As a result, people with cancers like chordoma are more likely to experience severe COVID-19-related complications. However, due to the vital nature of chordoma disease, regulatory authorities have advised against delaying or postponing chemotherapy or immunotherapy for chordoma disease care.
Healthcare facilities are introducing telehealth solutions to deliver services to cancer patients while preserving social distance in order to tackle the COVID-19 pandemic without jeopardising cancer patients’ health. Patients can make virtual consultation appointments with their physicians. To combat the spread of COVID-19 infection, healthcare providers are taking the following steps.
- Visitors are not permitted into hospitals, where only emergency cases are dealt with.
- All patients entering hospitals are being checked for potential COVID-19 symptoms.
- Healthcare providers are allowing patients to use telemedicine systems to schedule appointments.
Tailored Information as per niche requirement:
LIMITED TIME OFFER – Hurry Up!
Exclusive offer!!! Purchase the report at a discounted rate!!!
Get Discount For Buyers UPTO 30% OFF On Any Research Report
Buy Now with Discount for Premium Report 2021: https://www.coherentmarketinsights.com/promo/buynow/3979
Restraints:
Chemotherapeutic drugs approved for the treatment of chordoma are not always successful and can cause nausea, headaches, and hair loss, which is expected to limit market growth over the forecast period. The low prevalence of the disease and treatment limitations, as well as the high cost of diagnosis, treatment, and research and development, are all factors limiting market growth.
The global chordoma disease therapeutics market size is expected to be valued at US$ 5,296.31 million in 2020 and is expected to exhibit a CAGR of 6.7% over the forecast period (2020-2027).
Market Taxonomy:
Chordoma Disease Therapeutics Market, by Drug Class, is segmented into:
- Antimetabolites
- Anthracycline
- VEGFR Inhibitors
- EGFR Inhibitor
- Others
By Treatment Type:
- Chemotherapy
- Targeted Therapy
- Radiation Therapy
- Others
By End User:
- Hospitals
- Clinics
- Oncology Centers
- Others
By Region:
- North America
- Latin America
- Europe
- Asia Pacific
- Middle East
- Africa
View Press Release For More Information @ https://www.coherentmarketinsights.com/press-release/chordoma-disease-therapeutics-market-3247
Key Players:
Major players operating in the global chordoma disease therapeutics market include Sanofi SA, Astellas Pharma Inc., AstraZeneca plc, Amgen, Inc., GlaxoSmithKline Plc, Bavarian Nordic A/S, Boehringer Ingelheim International GmbH, Pfizer, Inc., Merck & Co., Inc., Bristol-Myers Squibb and Company, Novartis International AG, Bayer AG, Dr. Reddy’s Laboratories Ltd., and Mylan N.V.
Have a Look at Related Research Insights:
About Us:
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies, to not-for-profit organization, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.
To know more about us, please visit our website – www.coherentmarketinsights.com
Contact:
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837